Scolaris Content Display Scolaris Content Display

Apósitos hidrocoloides para la cicatrización de las úlceras del pie diabético

Appendices

Appendix 1. Search methods for the original version of the review ‐ January 2011

Electronic searches

We searched the following databases:

  • The Cochrane Wounds Group Specialised Register (searched 4 January 2012);

  • The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 4);

  • Ovid MEDLINE (1950 to December Week 3 2011);

  • Ovid MEDLINE (In‐Process & Other Non‐Indexed Citations, January 03, 2012);

  • Ovid EMBASE (1980 to 2011 Week 52);

  • EBSCO CINAHL (1982 to 30 December 2011).

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) using the following exploded MeSH headings and keywords:

#1 MeSH descriptor Occlusive Dressings explode all trees
#2 MeSH descriptor Biological Dressings explode all trees
#3 MeSH descriptor Alginates explode all trees
#4 MeSH descriptor Hydrogels explode all trees
#5 MeSH descriptor Silver explode all trees
#6 MeSH descriptor Honey explode all trees
#7 (dressing* or alginate* or hydrogel* or "foam" or "bead" or "film" or "films" or tulle or gauze or non‐adherent or "non adherent" or silver or honey or matrix):ti,ab,kw
#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
#9 MeSH descriptor Foot Ulcer explode all trees
#10 MeSH descriptor Diabetic Foot explode all trees
#11 diabet* NEAR/3 ulcer*:ti,ab,kw
#12 diabet* NEAR/3 (foot or feet):ti,ab,kw
#13 diabet* NEAR/3 wound*:ti,ab,kw
#14 (#9 OR #10 OR #11 OR #12 OR #13)
#15 (#8 AND #14)

The search strategies used in Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL can be found in Appendix 1, Appendix 2 and Appendix 3 respectively. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximising version (2008 revision) (Lefebvre 2011). We also combined the EMBASE and CINAHL searches with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN 2011). There were no restrictions on the basis of date or language of publication.

We searched for on‐going studies on the ISRCTN register (http://www.controlled‐trials.com/isrctn/) (last searched 22nd May 2011).

Searching other resources

We attempted to contact researchers to obtain any unpublished data when needed. We also searched the reference lists of the included studies and previous systematic reviews. We contacted appropriate manufacturers (Smith & Nephew, Convatec Ltd, Mölnlycke Health Care, 3M Healthcare, Coloplast Ltd) for details of any unpublished studies.

Appendix 2. Ovid MEDLINE search strategy

1 exp Occlusive Dressings/
2 exp Biological Dressings/
3 exp Alginates/
4 exp Hydrogels/
5 exp Silver/
6 exp Honey/
7 (dressing* or hydrocolloid* or alginate* or hydrogel* or foam or bead or film*1 or tulle or gauze or non‐adherent or non adherent or silver or honey or matrix).tw.
8 or/1‐7
9 exp Foot Ulcer/
10 exp Diabetic Foot/
11 (diabet* adj3 ulcer*).tw.
12 (diabet* adj3 (foot or feet)).tw.
13 (diabet* adj3 wound*).tw.
14 or/9‐13
15 8 and 14

Appendix 3. Ovid EMBASE search strategy

1 exp wound dressing/
2 exp alginic acid/
3 exp hydrogel/
4 exp SILVER/
5 exp HONEY/
6 (dressing* or hydrocolloid* or alginate* or hydrogel* or foam or bead or film*1 or tulle or gauze or non‐adherent or non adherent or silver or honey or matrix).tw.
7 or/1‐6
8 exp foot ulcer/
9 exp diabetic foot/
10 (diabet* adj3 ulcer*).tw.
11 (diabet* adj3 (foot or feet)).tw.
12 (diabet* adj3 wound*).tw.
13 or/8‐12
14 7 and 13

Appendix 4. EBSCO CINAHL search strategy

S11 S4 and S10
S10 S5 or S6 or S7 or S8 or S9
S9 TI diabet* N3 wound* or AB diabet* N3 wound*
S8 TI (diabet* N3 foot OR diabet* N3 feet) or AB (diabet* N3 foot OR diabet* N3 feet)
S7 TI diabet* N3 ulcer* or AB diabet* N3 ulcer*
S6 (MH "Foot Ulcer+")
S5 (MH "Diabetic Foot")
S4 S1 or S2 or S3
S3 TI (dressing* or alginate* or hydrogel* or foam or bead or film or films or tulle or gauze or non‐adherent or non adherent or honey or silver or matrix) or AB (dressing* or alginate* or hydrogel* or foam or bead or film or films or tulle or gauze or non‐adherent or non adherent or honey or silver or matrix)
S2 (MH "Honey")
S1 (MH "Bandages and Dressings+")

Appendix 5. Risk of bias criteria

1.  Was the allocation sequence randomly generated?

Low risk of bias

The investigators describe a random component in the sequence generation process such as: referring to a random number table; using a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.

High risk of bias

The investigators describe a non‐random component in the sequence generation process. Usually, the description would involve some systematic, non‐random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.

Unclear

Insufficient information about the sequence generation process to permit judgement of low or high risk of bias.

2.  Was the treatment allocation adequately concealed?

Low risk of bias

Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web‐based and pharmacy‐controlled randomisation); sequentially‐numbered drug containers of identical appearance; sequentially‐numbered, opaque, sealed envelopes.

High risk of bias

Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non­opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

Unclear

Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.

3.  Blinding ‐ was knowledge of the allocated interventions adequately prevented during the study?

Low risk of bias

Any one of the following.

  • No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding.

  • Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

  • Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non‐blinding of others unlikely to introduce bias.

High risk of bias

Any one of the following.

  • No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.

  • Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.

  • Either participants or some key study personnel were not blinded, and the non‐blinding of others likely to introduce bias.

Unclear

Any one of the following.

  • Insufficient information to permit judgement of low or high risk of bias.

  • The study did not address this outcome.

4.  Were incomplete outcome data adequately addressed?

Low risk of bias

Any one of the following.

  • No missing outcome data.

  • Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias).

  • Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.

  • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate.

  • For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size.

  • Missing data have been imputed using appropriate methods.

High risk of bias

Any one of the following.

  • Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups.

  • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate.

  • For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size.

  • ‘As‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.

  • Potentially inappropriate application of simple imputation.

Unclear

Any one of the following.

  • Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated, no reasons for missing data provided).

  • The study did not address this outcome.

5.  Are reports of the study free of suggestion of selective outcome reporting?

Low risk of bias

Any of the following.

  • The study protocol is available and all of the study’s pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way.

  • The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon).

High risk of bias

Any one of the following.

  • Not all of the study’s pre‐specified primary outcomes have been reported.

  • One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified.

  • One or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect).

  • One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis.

  • The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear

Insufficient information to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.

6.  Other sources of potential bias

Low risk of bias

The study appears to be free of other sources of bias.

High risk of bias

There is at least one important risk of bias. For example, the study:

  • had a potential source of bias related to the specific study design used; or

  • had extreme baseline imbalance; or

  • has been claimed to have been fraudulent; or

  • had some other problem.

Unclear

There may be a risk of bias, but there is either:

  • insufficient information to assess whether an important risk of bias exists; or

  • insufficient rationale or evidence that an identified problem will introduce bias.

'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 1

'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.

Comparison 1 Fibrous‐hydrocolloid (hydrofibre) dressing compared with basic wound contact dressing, Outcome 1 Number of ulcers healed.
Figuras y tablas -
Analysis 1.1

Comparison 1 Fibrous‐hydrocolloid (hydrofibre) dressing compared with basic wound contact dressing, Outcome 1 Number of ulcers healed.

Comparison 2 Hydrocolloid (matrix) dressing compared with foam dressing, Outcome 1 Number of ulcers healed.
Figuras y tablas -
Analysis 2.1

Comparison 2 Hydrocolloid (matrix) dressing compared with foam dressing, Outcome 1 Number of ulcers healed.

Comparison 3 Silver hydrocolloid dressing compared with alginate dressing, Outcome 1 Number of ulcers healed.
Figuras y tablas -
Analysis 3.1

Comparison 3 Silver hydrocolloid dressing compared with alginate dressing, Outcome 1 Number of ulcers healed.

Comparison 4 Iodine‐impregnated dressing compared with fibrous‐hydrocolloid (hydrofibre) dressing, Outcome 1 Number of ulcers healed.
Figuras y tablas -
Analysis 4.1

Comparison 4 Iodine‐impregnated dressing compared with fibrous‐hydrocolloid (hydrofibre) dressing, Outcome 1 Number of ulcers healed.

Study

Groups

Primary outcome: ulcer healing

Secondary: health‐related quality of life

Number and level of amputations

Adverse events, including pain

Cost

Ulcer recurrence

Heading 8

Clever 1995

Group A (n = 20): Hydrocolloid (polyurethane matrix) dressing

Group B (n = 20): Foam dressing

Number of ulcers healed:
Group A: 16

Group B: 14
Mean time to healing in days (SD)
Group A: 25.19 (23.52)

Group B: 20.43 (14.74)
Median time to healing in days
Group A: 15.5 (range 4 to 76)

Group B: 16.5 (range 4 to 52)
Wound size at 4 weeks mm2 (SD):
Group A: 32.37 (54.12)

Group B: 33.46 (75.22)

n/r

n/r

(Reasons not reported separately for 2 groups):
Group A: 1

Group B: 5

Mean number of dressing changes between clinical visits (SD):
Group A: 2.23 (2.19)

Group B: 2.37 (2.18)

n/r

Jeffcoate 2009

Group A (n = 103): Fibrous‐hydrocolloid

(hydrofibre) dressing

Group B (n = 108): Iodine‐impregnated dressing
Group C (n = 106): non‐adherent dressing, viscose filament gauze

Number of ulcers healed at 24 weeks:
Group A: 46

Group B: 48
Group C: 41
Mean time to healing in days (SD) (fixed at max of 168 days)
Group A: 125.8 (55.9)

Group B: 127.8 (54.2)
Group C  130.7 (52.4)

Mean Cardiff Wound Impact Schedule score at 24 weeks (SD)

Group A: Physical functioning: 71.4 (19.5).  Social functioning: 70.3 (25.4). Well being: 53.1 (19.9)
Group B: Physical functioning: 67.1 (23.6).  Social functioning: 69.7 (24.1). Well being: 51.0 (22.3) 
Group C: Physical functioning: 68.9 (19.1).  Social functioning: 69.8 (23.5). Well being: 50.2 (21.1) 
Other
Study also reports mean and SD for each of the eight domains of the SF‐36. No significant different between the groups for any domain.

Minor amputations (Below ankle):
Group A: 3
Group B: 1
Group C: 1
Major amputations (Above knee)
Group A: 1
Group B: 0
Group C: 1

Non‐serious adverse events
Group A: 227

Group B: 239
Group C: 244
Serious adverse events
Group A: 28

Group B: 37
Group C: 35

Cost in GBP per patient for dressing management:
Mean (95% CI)

Group A: 191.33 (148.41 to 234.25)
Group B: 183.60 (128.92 to 238.21)
Group C: 141.18 (108.18 to 174.17)
Cost in GBP of professional time in managing foot ulcers: Mean (95% CI)

Group A: 459.87 (354.78 to 564.97)
Group B: 556.90 (422.32 to 691.48)
Group C: 448.86 (348.68 to 549.03
Cost in GBP of generating a healed ulcer using non‐adherent dressing (Group C): 362.

Cost in GBP of generating an additional healed ulcer:

Group A: 836

Group B: 848

At same site
Group A: 3
Group B: 7
Group C: 3

Jude 2007

Group A (n = 67): Fibrous‐hydrocolloid (hydrofibre) dressing with 1.2% ionic silver  
Group B (n = 67): Calcium‐alginate dressing

Number of ulcers healed in 8 weeks
Group A: 21
Group B: 15
Velocity of healing cm2/week (SD):
Group A: 0.29 (0.33) (n = 61)
Group B: 0.26 (0.90) (n = 61)
Velocity of healing as % per week (SD):
Group A: 11.6 (17.7) (n = 61)   
Group B: 10.0 (15.5)  (n = 61)                 
Mean time in days to healing (SD):
Group A: 52.6 (1.8)       
Group B: 57.7 (1.7)                                                                
Reduction in ulcer area in 8 weeks:
Group A: 58.1 (53.1).
Group B: 60.5 (42.7). 
Reduction in ulcer depth (cm) at 8 weeks (SD):
Group A:  0.25 (0.49)   
Group B:  0.13 (0.37)   


                              

n/r

n/r

Group A: 25 participants experienced one or more events. Death = 1; Infection = 14. 8 participants discontinued treatment due to AE.                                            
Group B: 26 participants experienced adverse event. Death = 1; Infection = 8. 13 participants discontinued treatment due to AE.                 

Mean number of dressing changes during study:
Group A: 21.9    
Group B: 20.8   

n/r

Kuo 2012

Group A (n = 12): fibrous‐hydrocolloid (hydrofibre) dressing
Group B (n = 12): cream contained extracts from two botanical raw materials, P. amboinicus and C. asiatica.

Percent change in wound size (from baseline ‐ assumed to 14 days).

Median and (IQR)

Group A: ‐22.64 (‐36.90 to ‐3.20)

Group B: ‐ 27.18(‐38.86 to 36.10)

Reported in paper as not statistically significant from Mann‐Whitney U test. P = 0.673

n/r

n/r

Number of people with one or more adverse events

Group A: 5/12 (41.7%)

Group B: 5/12 (41.7%)

Piaggesi 2001

Group A (n = 10): Fibrous‐hydrocolloid

(hydrofibre) dressing
Group B (n = 10): Saline‐moistened gauze dressing

Number of ulcers healed (during period of study):
Group A: 9
Group B: 10
Healing time in days (mean) (SD)
Group A: 127 (46 days)
Group B: 234 (61 days) 
Median % reduction in lesion volume at 8 weeks follow up (interquartile range):
Group A: 50 (26)           
Group B: 35 (15) 
Median % of granulation tissue at 8 weeks follow up (interquartile range)
Group A: 60 (40)               
Group B: 32.5 (10)                       

    

n/r

Group A: Amputation of a lesser toe = 3; Amputation of 2 lesser toes = 1; Metatarsal resection = 1
Group B: Amputation of a lesser toe = 2; Metatarsal resection = 1

Group A: Maceration of peri‐lesional skin = 1; Infective complications = 1
Group B: Maceration of peri‐lesional skin = 2; Infective complications = 3    

Average number of days between dressings changes (SD)
Group A: 2.1 (0.6)
Group B: 2.4 (0.3)

n/r

Figuras y tablas -
Analysis 5.1

Comparison 5 Trial data, Outcome 1 Trial data.

Summary of findings for the main comparison. Fibrous‐hydrocolloid (hydrofibre) dressing compared to basic wound contact dressing for healing diabetic foot ulcers

Fibrous‐hydrocolloid (hydrofibre) dressing compared to basic wound contact dressing for healing diabetic foot ulcers

Patient or population: patients with healing diabetic foot ulcers
Settings: Any
Intervention: Fibrous‐hydrocolloid (hydrofibre) dressing
Comparison: basic wound contact dressing

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Basic wound contact dressing

Fibrous‐hydrocolloid (hydrofibre) dressing

Number of ulcers healed

Low1

RR 1.01
(0.74 to 1.38)

229
(2 studies)

⊕⊕⊕⊝
moderate2

340 per 1000

343 per 1000
(252 to 469)

Moderate1

530 per 1000

535 per 1000
(392 to 731)

High1

650 per 1000

657 per 1000
(481 to 897)

HRQoL

See comment

See comment

Not estimable

0
(0)

See comment

One study measured HRQoL at 24 weeks follow‐up. Data from several domains are presented in the report, with no statistically significant difference observed.

Adverse events

See comment

See comment

Not estimable

0
(0)

See comment

AEs for two studies ‐ very similar numbers in each arms. Data not analysed here as not independent ‐ that is one person could have multiple events or due to limited data.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Baseline risk of healing obtained from external source in which data from 27,630 patients with a diabetic neuropathic foot ulcer was used to develop a simple prognostic model to predict likelihood of ulcer healing (Margolis DJ, Allen‐Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: predicting which ones will not heal. Am J Med. 2003;115:627‐31). It is important to note that given an outcome of ulcer healing, low risk refers to a low risk of healing and thus reflects the most severe patient populations. Conversely high risk refers to a high risk of healing.
2 108 participants achieved the endpoint of healing in the two studies, this is an underpowered comparison. The confidence interval around the estimate of relative risk is consistent with a 26% relative reduction in healing with hydrocolloid and a 38% relative increase in healing with hydrocolloid.

Figuras y tablas -
Summary of findings for the main comparison. Fibrous‐hydrocolloid (hydrofibre) dressing compared to basic wound contact dressing for healing diabetic foot ulcers
Table 1. Summary of studies

First author

Group A

Group B

Group C

Duration of follow up

% healed data

Clever 1995

Hydrocolloid (polyurethane matrix) dressing (Cutinova Hydro, S&N Hlth)

Foam dressing (Allevyn, S&N Hlth)

16 weeks

yes

Jeffcoate 2009

Fibrous‐hydrocolloid (hydrofibre) dressing (Aquacel, ConvaTec)

Iodine‐impregnated dressing (Inadine, Johnson & Johnson)

Non‐adherent dressing (Johnson & Johnson)

24 weeks

yes

Jude 2007

Fibrous‐hydrocolloid (hydrofibre) dressing with 1.2% ionic silver (Aquacel Ag, ConvaTec)

Calcium‐alginate dressing (Algosteril, S&N Hlth)

8 weeks

yes

Kuo 2012

Fibrous‐hydrocolloid (hydrofibre) dressing (Aquacel, ConvaTec)

Cream contained extracts from two botanical raw materials, P. amboinicus and C. asiatica.(Active ingredient 1.25%)

2 weeks

No

Piaggesi 2001

Fibrous‐hydrocolloid (Hydrofibre) dressing (Aquacel, ConvaTec)

Saline‐moistened gauze

Not reported (maximum follow up was 350 days)

yes

Figuras y tablas -
Table 1. Summary of studies
Comparison 1. Fibrous‐hydrocolloid (hydrofibre) dressing compared with basic wound contact dressing

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of ulcers healed Show forest plot

2

229

Risk Ratio (M‐H, Random, 95% CI)

1.01 [0.74, 1.38]

Figuras y tablas -
Comparison 1. Fibrous‐hydrocolloid (hydrofibre) dressing compared with basic wound contact dressing
Comparison 2. Hydrocolloid (matrix) dressing compared with foam dressing

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of ulcers healed Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

Figuras y tablas -
Comparison 2. Hydrocolloid (matrix) dressing compared with foam dressing
Comparison 3. Silver hydrocolloid dressing compared with alginate dressing

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of ulcers healed Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

Figuras y tablas -
Comparison 3. Silver hydrocolloid dressing compared with alginate dressing
Comparison 4. Iodine‐impregnated dressing compared with fibrous‐hydrocolloid (hydrofibre) dressing

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Number of ulcers healed Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

Figuras y tablas -
Comparison 4. Iodine‐impregnated dressing compared with fibrous‐hydrocolloid (hydrofibre) dressing
Comparison 5. Trial data

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Trial data Show forest plot

Other data

No numeric data

Figuras y tablas -
Comparison 5. Trial data